Therapeutic dendrimer

US12071517B2 · kind B2 · utility

Assignee

• Starpharma Pty Ltd. · AU

Inventors

• David Owen · Melbourne, AU
• Brian Devlin Kelly · Melbourne, AU
• Jacinth Kincaid Fairley · Melbourne, AU
• Jeremy Robert Arthur Paull · Sydney, AU
• Stephanie Ruth Edmondson · Preston, AU
• Nicola Jane Main · Preston, AU

Key dates

• Filing date: Aug 30, 2021
• Grant date: Aug 27, 2024
• Expiry date: Feb 9, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C08G83/004
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.